Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 11-15 |
| Journal | European Urology |
| Volume | 79 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Jan 2021 |
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: European Urology, Vol. 79, No. 1, 01.2021, p. 11-15.
Research output: Contribution to journal › Editorial › Academic › peer-review
TY - JOUR
T1 - European Association of Urology Position Paper on the Prevention of Infectious Complications Following Prostate Biopsy
AU - Pilatz, Adrian
AU - Veeratterapillay, Rajan
AU - Dimitropoulos, Konstantinos
AU - Omar, Muhammad Imran
AU - Pradere, Benjamin
AU - Yuan, Yuhong
AU - Cai, Tommaso
AU - Mezei, Tunde
AU - Devlies, Wout
AU - Bruyère, Franck
AU - Bartoletti, Riccardo
AU - Köves, Bela
AU - Geerlings, Suzanne
AU - Schubert, S. ren
AU - Grummet, Jeremy
AU - Mottet, Nicolas
AU - Wagenlehner, Florian
AU - Bonkat, Gernot
N1 - Funding Information: Funding support: This work is supported by the European Association of Urology Guidelines Office. Funding Information: Conflict of interest: Adrian Pilatz certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript are the following: Gernot Bonkat is a company consultant for Vifor Pharma, Janssen, Cilag, Zambon, and IBSA; has received speaker honoraria from Vifor Pharma, Bionorica, and IBSA; and has received fellowship and travel grants from Astellas, Lilly, and Vifor Pharma. Riccardo Bartoletti is a company consultant for GSK; has received speaker honoraria from Becton and Dickinson; and has received fellowship and travel grants from IDI Pharma, Ipsen, Ab Mediac-procept, and MV Medical Solutions. Franck Bruyère has received speaker honorarium from Boston Scientific and Ipsen, and is a trail participant for CYSDUA. Tommaso Cai has received speaker honorarium from Zambon and Bayer. Suzanne Geerlings is a company consultant for and has received speaker honorarium from Vifor Pharma. Bela Köves is a company consultant for F. Hoffmann-La Roche and OM Pharma; has received speaker honorarium from Vifor Pharma and Bionorica; and has received fellowship and travel groups from the EAU. Sören Schubert is a company consultant for Achaogen, Bionorica, Janssen, Pfizer, RosenPharma, and Shionogi; has received speaker honorarium from Astra Zeneca; has participated in trials for Achaogen, Bionorica, Merlion, MSD, and Shionogi; and has received grants/research supports from Enteris, Helperby therapeutics, LeoPharma, and Vifor Pharma. Adrian Pilatz has received speaker honorarium from Vifor Pharma. Wout Devlies has participated in trials for Janssen and received a travel grant from Ipsen. Nicolas Mottet is a company consultant for Janssen, GE, BMS, Sanofi, and Astellas; has received speaker honoraria from Astellas, Pierre Fabre, Steba, Janssen, and Ferring; and has received fellowships and travel grants from Astellas, Ipsen, Sanofi, Janssen, and Roche. Jeremy Grummet received speaker honorarium from Mundipharma, a travel grant from Astellas, and a research grant from Cancer Australia; he is the owner of MRI PRO Pty Ltd., an online training platform. Yuhong Yuan, Imran Omar, Benjamin Pradere, Rajan Veeratterapillay, and Tunde Mezei have nothing to declare. Publisher Copyright: © 2020 European Association of Urology Copyright: Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2021/1
Y1 - 2021/1
N2 - The transperineal approach is preferred to reduce prostate biopsy (PB)-related infections. Fluoroquinolones are suspended for prophylaxis of PB in the European Union; therefore, alternative antibiotics based on local resistance, or targeted prophylaxis, in conjunction with povidone-iodine rectal preparation are recommended for transrectal PB.
AB - The transperineal approach is preferred to reduce prostate biopsy (PB)-related infections. Fluoroquinolones are suspended for prophylaxis of PB in the European Union; therefore, alternative antibiotics based on local resistance, or targeted prophylaxis, in conjunction with povidone-iodine rectal preparation are recommended for transrectal PB.
UR - http://www.scopus.com/inward/record.url?scp=85095852869&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.eururo.2020.10.019
DO - https://doi.org/10.1016/j.eururo.2020.10.019
M3 - Editorial
C2 - 33172721
SN - 0302-2838
VL - 79
SP - 11
EP - 15
JO - European Urology
JF - European Urology
IS - 1
ER -